Phase II/III, double-blind, RCT shown fasinumab (nerve growth factor inhibitor) at higher doses (9mg q4 or q8wks), but not lower doses, improved chronic low back pain w/ best responses at wk 16.. Rapid OA progression seen more w/ FAS (3.8%) vs PBO (0.7%) https://t.co/OfdEsAZuDe